RxDoctor Payments Data

Michael Duong, MD

Cardiovascular Disease · Everett, WANPI 1043256803

Payments from drug & device makers

$5,701in general payments, 2019–2025

Across 81 payments — averaging $70.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Edwards Lifesciences$1K
  • Abiomed$306
  • Boston Scientific$264
  • Esperion Therapeutics, Inc.$123
  • Abbott$89
  • plus $295 from 8 others

What the payments were for

  • Travel & lodging$3,16455%
  • Food & beverage$2,53845%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,701 in reported general payments places this provider in the 75th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$208,727
Medicare patients
315
Services billed
2,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$215,841
EntrestoSacubitril/Valsartan112$122,085
Repatha SureclickEvolocumab93$67,124
JardianceEmpagliflozin45$43,752
XareltoRivaroxaban37$37,849
FarxigaDapagliflozin Propanediol26$21,332
Repatha SyringeEvolocumab23$18,899
Praluent PenAlirocumab23$14,740
Atorvastatin Calcium485$5,644
Rosuvastatin Calcium346$4,794
Metoprolol Succinate380$4,077
Ezetimibe194$3,424
Losartan Potassium254$2,955
Icosapent Ethyl14$2,727
Amlodipine Besylate342$2,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$34$21,33226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →